Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 317 results for "dr lal pathlabs"

Dr Lal PathLabs to play volume game, says CEO Manchanda
VC Circle

Dr Lal PathLabs to play volume game, says CEO Manchanda

Gurgaon-based Dr Lal PathLabs Ltd is India's second-largest diagnostics chain. The company, backed by private equity firms TA Associates and WestBridge, made a spectacular debut on stock markets in December last year. It has a network of 171... ... VC Circle, 5 days ago
Dr Lal PathLabs to expand network Chandigarh Tribune, 2 months ago

12 images for dr lal pathlabs

India Infoline, 1 month ago
Financial Express, 2 weeks ago
Livemint.com, 3 days ago
Money Control, 4 weeks ago
Moneycontrol.com, 4 weeks ago
VC Circle, 5 days ago
Business Standard India, 4 weeks ago
Livemint.com, 1 month ago
Livemint.com, 1 month ago
Financial Express, 4 weeks ago

Dr Lal PathLabs, Emami, Havells Among Citi's Top Midcap Bets

Dr Lal PathLabs made a stellar debut in stock markets last year The Bombay Stock Exchange's sub-index of midcap stocks is up 10 per cent over the last one year as compared to 1 per cent dip in the broader Sensex. This outperformance in midcap ...
 NDTV1 week ago Technological Innovations and Business Strategy go hand in hand at Dr Lal Pathlabs  EHealth Magazine1 month ago Healthcare sector a shot in the arm for co: Dr Lal PathLabs  Money Control2 months ago Dr Lal PathLabs stock on a high, rides on healthcare growth  Money Control2 months ago

Buy Dr Lal Pathlabs, target Rs 1140: Citigroup

Citigroup maintains buy on Dr. Lal Pathlabs post-March quarter results with a 12-month target price of Rs 1140. The management expects to surpass industry growth of 15%-17%. The global investment bank sees margin decline of 100 - 200 bps on ...
 Economic Times3 weeks ago Dr. Lal PathLabs to hold AGM  Capital Market3 weeks ago Dr Lal PathLabs recommends dividend  Money Control4 weeks ago Board of Dr. Lal PathLabs recommends final dividend  Business Standard3 weeks ago
[x]  

Expect Dr Lal PathLabs to surpass industry growth in FY17: CEO

CEO Om Manchanda expects planned expansion of central lab network in Kolkata and Lucknow will help Dr Lal PathLabs to sustain margins in FY17. Diagnostics space which has low penetration in India makes it a good pitch for companies like Dr Lal PathLab, ...
 Money Control2 weeks ago Diagnostic industry is growing at 17% & we continue to see same momentum: Om Manchanda, CEO, Dr Lal PathLabs  Economic Times3 weeks ago May outperform industry's 17% FY17 growth rate forecast: Dr Lal  Money Control3 weeks ago Diagnostic sector is growing at 17% & we continue to see same momentum: Om Manchanda, CEO, Dr Lal PathLabs  Economic Times3 weeks ago

Dr Lal Pathlabs standalone net profit rises 28.09% in the March 2016 quarter

Sales rise 14.96% to Rs 191.29 crore Net profit of Dr Lal Pathlabs rose 28.09% to Rs 32.47 crore in the quarter ended March 2016 as against Rs 25.35 crore during the previous quarter ended March 2015. Sales rose 14.96% to Rs 191.29 crore in the quarter ended ...
 Business Standard4 weeks ago Dr Lal Pathlabs consolidated net profit rises 19.79% in the March 2016 quarter  Business Standard4 weeks ago
Money Control

Dr Lal PathLabs to acquire Delta Ria and Pathology

Diagnostics chain Dr Lal PathLabs has decided to acquire Delta Ria and Pathology, and purchase additional 10% stake each in two group companies Paliwal Diagnostics and Paliwal Medicare to raise its stake to 80%. Delta Ria and Pathology will be ...
 VC Circle3 weeks ago Dr. Lal PathLabs approves acquisition of Delta Ria and Pathology  Reuters UK4 weeks ago
[x]  
Financial Express

Dr Lal PathLabs shares gain 2% today on expansion plans; up 80% sincelisting

Dr Lal PathLabs shares jumped over 2 per cent in the early trade on Friday on reports that the diagnostic services provider is planningto expand its footprint across India. While deepening its presence in the North Indian market where it already has ...
 Yahoo! India2 weeks ago Dr Lal PathLabs shares gain today on expansion plans; up 80% since listing  Financial Express2 weeks ago Dr Lal Pathlabs allots equity shares  Business Standard2 months ago

Dr Lal PathLabs eyes wider footprint to drive growth

Diagnostic services provider DrLal PathLabs is looking at expanding its presence pan-India tobe a key driver for the next phase of growth for the company.
 Money Control2 weeks ago Dr. Lal PathLabs eyes expanding footprint across India  HT Syndication2 weeks ago
[x]  

Fortis to chart new course of action for SRL Diagnostics

SRL Diagnostic will soon be vertically demerged from its parent company After the successful listing of Dr Lal Pathlabs in December 2015 and recently Thyrocare's success in the stock market has enthused the promoter company of SRL Diagnostics to ...
 Financial Express2 weeks ago
Moneycontrol.com

This is why 2016 IPOs have been a hit with investors: Expert

The IPOs of Thyrocare, TeamLease, Ujjivan Finance, Alkem Labs and Dr Lal Pathlabs were subscribed 73, 66, 41, 33 and 21 times respectively.
 Money Control1 month ago Thyrocare, Ujjivan IPOs to hit markets next week  Times of India2 months ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less